相关实验视频

Updated: Jul 15, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

在低增殖早期胰腺管道腺癌中进行CDKs功能分析

Shikai Zhu^1,2, Huining Yang¹, Lingling Liu³

¹Sichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Laboratory Medicine, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine,University of Electronic Science and Technology of China, Chengdu, China.

Journal of bioinformatics and systems biology : Open access

|September 25, 2023

概括

循环素依赖性激酶 (CDK) 驱动胰腺管腺癌 (PDAC) 的进展. 向CDK可能通过影响转移和茎状,而不仅仅是扩散,为PDAC提供新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物信息学是一种生物信息学.

背景情况:

胰腺管道腺癌 (PDAC) 由于预后不佳和发病率不断增加,因此具有重大临床挑战.
早期PDAC的进展和治疗目标仍然不完全理解.

研究的目的:

调查 1,2,4 和 6 个循环素依赖性基因酶 (CDKs) 在早期 PDAC 的进展中的作用.
探索潜在的细胞周期独立机制,通过这些机制,CDKs影响PDAC的攻击性.

主要方法:

在癌症基因组图谱 (TCGA) 中对140名I/II期PDAC患者的临床病理学,mRNA表达和治疗数据的生物信息分析.
对CDK表达水平与患者存活率之间的相关性分析,以及与关键癌症特征相关的蛋白质的关联.
在低和高增殖的PDAC细胞系中使用CDK淘汰/抑制进行实验验证,以评估对特定蛋白质表达的影响.

主要成果:

增加CDK1,CDK2,CDK4或CDK6的表达与早期PDAC患者中较短的中位生存期有关.
在低增殖的PDAC中,CDK表达与参与亡,转移,免疫力和干性的蛋白质相关.
在低增殖PDAC细胞中,CDK1抑制抑制了转移和干性相关蛋白 (AHR,POU5F1),表明细胞周期独立的功能.

结论:

CDKs通过细胞增殖和其他机制,包括细胞亡,转移,免疫力和干性,促进PDAC的进展.
CDK1在通过细胞循环独立的途径调节PDAC转移和干性方面发挥着关键作用.
向CDK可以代表PDAC的新治疗策略,解决瘤进展的多个方面.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.循环素依赖的激酶酶.早期阶段早期阶段免疫性免疫性免疫性低增殖的癌细胞是癌细胞的低增殖.转移转移转移转移胰腺管道腺癌 (PDAC) 是一种幸存的生存方式

更多相关视频

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...